Shots:
- UCB to receive $120M and is eligible to receive $2B as cost reimbursement, development, and commercial milestones as well as royalties on sales of the therapies, if Roche proceeds the clinical development. Roche to get an exclusive license to develop and commercialize UCB0107 for AD
- UCB to fund and perform a POC study in AD and, upon the availability of the results of that study while Roche has the right to progress with the development or return full rights back to UCB
- UCB0107 is an IgG4 mAb targeting a central Tau epitope, being developed to block/reduce the spread of Tau pathology. UCB continues to develop UCB0107 in PSP, with anticipated initiation of P-III study in Q2’21
Click here to read full press release/ article | Ref: PRNewswire | Image: PharmaShots
